Skip to main content

Funding for Global Cancer Research and Training

The Center for Global Health (CGH) funds research to reduce the global burden of cancer and offers research training opportunities for investigators to strengthen their research abilities.

Sort the table below for current funding opportunities for global cancer research and research training.

Learn more about grants and funding from the National Institutes of Health.

Subscribe for email updates from CGH.

Current Funding Opportunities

Title Announcement Number Opening Date Expiration Date Additional Resources
Notice of Special Interest (NOSI): Precision Imaging of Oral Lesions NOT-DE-21-010 08/06/2021 09/10/2024  
Mobile Health: Technology and Outcomes in Low- and Middle-Income Countries (R21/R33 - Clinical Trial Optional) PAR-21-303 08/04/2021 12/10/2022  
SBIR Contract Topic 440 - Cancer Prevention and Diagnosis Technologies for Low-resource Settings (with HPV Dx set aside) NIH/NCI 440     Receipt date: October 28, 2021, 5:00 p.m. EST
Notice of Special Interest (NOSI): National Cancer Institute SBIR/STTR Program Announcement Regarding Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings NOT-CA-21-062 07/23/2021 09/07/2024 This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.
Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01 Clinical Trial Optional) RFA-CA-21-056 08/25/2021 12/16/2021  
Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional) RFA-CA-21-030 02/18/2021 06/03/2021 This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.
Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries (D43 Clinical Trial Not Allowed) RFA-CA-20-031 04/14/2020 06/25/2021 D43 Pre-Application Webinar Slides
RFA-CA-20-031 Frequently Asked Questions
International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Not Allowed PAR-21-104 01/04/2021 03/09/2023  
International Research Scientist Development Award (IRSDA) (K01 Independent Clinical Trial Required) PAR-21-105 01/04/2021 03/09/2023  
The East Asia Science and Innovation Area Joint Research Program e-ASIA JRP call for applications     Solicitation Guidelines
Notice of Special Interest (NOSI): Innovative Molecular Analysis Technologies for Low-Resource Settings Globally NOT-CA-21-025 01/04/2020 09/30/2021  
Notice of Special Interest: Academy of Finland (AKA) – National Institutes of Health (NIH) Partnership Program NOT-OD-21-021 11/13/2020    
Notice of Special Interest (NOSI): Advancing Head and Neck Cancer Early Detection Research (AHEAD) NOT-CA-20-031 03/09/2020 01/08/2022  
Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments NOT-CA-20-025 02/10/2020 05/08/2022 Interested applicants must submit applications for this initiative using one of the following Dissemination and Implementation Research in Health FOAs:
Microbial-based Cancer Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) PAR-19-194 05/16/2019 05/08/2022 Microbial-based Cancer Therapy - Technologies to Overcome Cancer
Microbial-based Cancer Therapy -Bugs as Drugs (R01 Clinical Trial Not Allowed) PAR-19-193 05/05/2019 05/08/2022 Microbial-based Cancer Therapy - Technologies to Overcome Cancer
Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) PAR-19-274 05/08/2019 05/08/2022  
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional) PAR-19-275 05/16/2019 05/08/2022  
Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed) PAR-19-276 05/16/2019 05/08/2022  

Training Opportunities

Explore cancer research programs and research training offered and funded through CGH.

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Funding for Global Cancer Research and Training was originally published by the National Cancer Institute.”